Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Excellent Response to MEK Inhibition in an AGK-BRAF Gene Fusion Driven Carcinoma: Case Report and Literature Review.

Anticancer research - 1 Jan 2022

Domen Andreas, Paesschen Carl VAN, Zwaenepoel Karen, Lambin Suzan, Pauwels Patrick, Rasschaert Marika, Segelov Eva, Peeters Marc, Prenen Hans

Abstract excerpt

BACKGROUND: Soft tissue myoepithelial carcinomas (STMC) are a rare, malignant subgroup of myoepithelial tumors that arise typically in glandular or ductal tissues, but also in the bone and soft and cutaneous tissues. Due to its rarity, there is no consensus regarding the treatment of STMC, including chemotherapy or other systemic agents for metastatic STMC. CASE REPORT: A chemotherapy- and regorafenib-refractory...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma
Share to Enzyme Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mitogen-Activated Protein Kinase Kinases

Share to Oncogene Proteins, Fusion

Share to Phosphotransferases (Alcohol Group Acceptor)

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Soft Tissue Neoplasms

Source

Identifiers

PMID: 34969747
DOI: 10.21873/anticanres.15495

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Excellent Response to MEK Inhibition in an AGK-BRAF Gene Fusion Driven Carcinoma: Case Report and Literature Review.PMID 34969747Read ↗

Near Complete Response to Trametinib Treatment in Histiocytic Sarcoma Harboring a Somatic KRAS Mutation.Semantic proximity Read ↗

Myoepithelial carcinoma with RB1 mutation: remarkable chemosensitivity to carcinoma of unknown origin therapy.Semantic proximity Read ↗

Ex vivo assessment of targeted therapies in a rare metastatic epithelial-myoepithelial carcinoma.Semantic proximity Read ↗

Combined treatment for a rare malignant glomus tumor of the esophagus with pulmonary and liver metastases: a case report and review of literatureSemantic proximity Read ↗

Exceptional Response to MEK Inhibition in a Patient With RAF1-Mutant Myxofibrosarcoma: Case Report and Mechanistic OverviewSemantic proximity Read ↗

Efficacy of MEK inhibitors in Erdheim-Chester disease: impact of MAPK pathway pathogenic variantsSemantic proximity Read ↗

Concomitant MEK and Cyclin Gene Alterations: Implications for Response to Targeted Therapeutics.Semantic proximity Read ↗

RAF-independent MEK mutations drive refractory histiocytic neoplasms but respond to ERK inhibition.Semantic proximity Read ↗

Emerging therapeutic targets in bladder cancer.Semantic proximity Read ↗

Tissue-Specific Mutations in BRAF and EGFR Necessitate Unique Therapeutic Approaches.Semantic proximity Read ↗

Exceptional Response of BRAFV600E-Mutated Acinar Cell CUP to BRAF/MEK Inhibition.Semantic proximity Read ↗

MET signaling drives acquired resistance to erdafitinib in muscle-invasive bladder cancer cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.